AlcoTail - Implementation of Tailored Interventions

RecruitingOBSERVATIONAL
Enrollment

4,200

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Alcohol ConsumptionPsychoactive Substance Use
Interventions
BEHAVIORAL

Harmful alcohol use treatment

Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.

BEHAVIORAL

Non-prescribed psychoactive medicinal use treatment

Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.

Trial Locations (1)

Unknown

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Lovisenberg Diakonale Hospital

OTHER

collaborator

Oslo Municipality

OTHER_GOV

lead

Oslo University Hospital

OTHER